Pharmaceuticals & Life Sciences

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (“Baergic”), announce that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome”),

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics Read More »

‘Everybody’s Talking About It’: Metsera Bidding War Grips the Obesity Field

Novo Nordisk and Pfizer made their presence known on the first day of the annual ObesityWeek conference. On Tuesday, the large drugmakers escalated their bidding war for Metsera, a Phase 2 biotech creating long-acting injectables and oral treatments for obesity. Both companies increased their offers to acquire Metsera, and a Delaware judge let the dueling

‘Everybody’s Talking About It’: Metsera Bidding War Grips the Obesity Field Read More »

Inside HPE Europe 2025 | The Future of Life Sciences Investment

European life sciences businesses have been closely tracking geopolitics and global policy changes over the past 12 months, particularly as the new administration in the United States heightens its focus on drug pricing. Against this backdrop, hundreds of healthcare professionals, investors, and industry changemakers gathered in London for McDermott Will & Schulte’s annual HPE Europe

Inside HPE Europe 2025 | The Future of Life Sciences Investment Read More »

QIAGEN to Acquire Parse Biosciences, Expanding Its Sample Technologies Portfolio into Highly Scalable Single-Cell Solutions

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The acquisition will significantly expand QIAGEN’s Sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up

QIAGEN to Acquire Parse Biosciences, Expanding Its Sample Technologies Portfolio into Highly Scalable Single-Cell Solutions Read More »

Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical

Evoke Pharma, Inc. (NASDAQ: EVOK) (“Evoke”), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and QOL Medical, LLC (“QOL Medical”), a privately held biopharmaceutical company specializing in treatments for GI and rare diseases, announce that they have entered into a definitive agreement pursuant

Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical Read More »

Scroll to Top